Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:FULC NASDAQ:OCX NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.89+0.4%$6.50$3.93▼$7.54$353.31M1.67682,307 shs536,782 shsFULCFulcrum Therapeutics$7.66+11.3%$7.06$2.32▼$9.30$414.35M2.82381,469 shs599,040 shsOCXOncoCyte$3.18+16.3%$3.07$1.92▼$4.75$90.80M0.9758,260 shs100,514 shsRCKTRocket Pharmaceuticals$3.28+1.5%$3.12$2.19▼$22.01$353.93M0.625.81 million shs1.45 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%+0.88%+9.89%+2.23%+23.70%FULCFulcrum Therapeutics0.00%+18.21%+12.48%+5.66%-7.15%OCXOncoCyte0.00%0.00%0.00%+6.90%-0.47%RCKTRocket Pharmaceuticals0.00%0.00%+6.15%+6.84%-81.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.89+0.4%$6.50$3.93▼$7.54$353.31M1.67682,307 shs536,782 shsFULCFulcrum Therapeutics$7.66+11.3%$7.06$2.32▼$9.30$414.35M2.82381,469 shs599,040 shsOCXOncoCyte$3.18+16.3%$3.07$1.92▼$4.75$90.80M0.9758,260 shs100,514 shsRCKTRocket Pharmaceuticals$3.28+1.5%$3.12$2.19▼$22.01$353.93M0.625.81 million shs1.45 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%+0.88%+9.89%+2.23%+23.70%FULCFulcrum Therapeutics0.00%+18.21%+12.48%+5.66%-7.15%OCXOncoCyte0.00%0.00%0.00%+6.90%-0.47%RCKTRocket Pharmaceuticals0.00%0.00%+6.15%+6.84%-81.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.50183.02% UpsideFULCFulcrum Therapeutics 2.63Moderate Buy$7.57-1.16% DownsideOCXOncoCyte 2.75Moderate Buy$6.0690.94% UpsideRCKTRocket Pharmaceuticals 2.41Hold$16.73410.16% UpsideCurrent Analyst Ratings BreakdownLatest OCX, RCKT, FULC, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $10.008/20/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/18/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/15/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $20.008/11/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.008/8/2025RCKTRocket PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.007/25/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.00 ➝ $10.007/25/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$9.00 ➝ $4.007/24/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $12.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M100.95N/AN/A$1.01 per share6.82FULCFulcrum TherapeuticsN/AN/AN/AN/A$4.51 per shareN/AOCXOncoCyte$3.84M23.63N/AN/A($0.70) per share-4.54RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.709.84N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)OCXOncoCyte-$60.66M-$3.53N/AN/AN/A-1,516.06%-215.59%-27.23%N/ARCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)Latest OCX, RCKT, FULC, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65FULCFulcrum TherapeuticsN/A24.4224.42OCXOncoCyte0.203.743.70RCKTRocket Pharmaceuticals0.056.396.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%FULCFulcrum Therapeutics89.83%OCXOncoCyte55.35%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%FULCFulcrum Therapeutics7.00%OCXOncoCyte2.05%RCKTRocket Pharmaceuticals24.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million47.74 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableOCXOncoCyte12028.60 million28.01 millionNo DataRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableOCX, RCKT, FULC, and ABEO HeadlinesRecent News About These CompaniesRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 5 at 3:29 AM | americanbankingnews.comMPM Bioimpact LLC Buys 597,706 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4 at 7:02 AM | marketbeat.comFrazier Life Sciences Management L.P. Sells 400,000 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4 at 7:00 AM | marketbeat.comRocket Pharmaceuticals, Inc. $RCKT Shares Bought by Baker BROS. Advisors LPSeptember 4 at 6:27 AM | marketbeat.comRussell Investments Group Ltd. Sells 767,219 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4 at 3:27 AM | marketbeat.com629,749 Shares in Rocket Pharmaceuticals, Inc. $RCKT Acquired by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comNuveen LLC Makes New Investment in Rocket Pharmaceuticals, Inc. $RCKTSeptember 2, 2025 | marketbeat.comJump Financial LLC Invests $1.69 Million in Rocket Pharmaceuticals, Inc. $RCKTAugust 30, 2025 | marketbeat.comSynovus Financial Corp Has $1.86 Million Stock Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 29, 2025 | marketbeat.comElisabeth Bjork Buys 10,000 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockAugust 28, 2025 | insidertrades.comAlphaQuest LLC Increases Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 28, 2025 | marketbeat.comRocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunitiesAugust 25, 2025 | msn.comWellington Management Group LLP Reduces Stock Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 25, 2025 | marketbeat.comWilliam Blair Issues Negative Forecast for RCKT EarningsAugust 24, 2025 | marketbeat.comEMA says Rocket Pharmaceuticals withdraws MA application for FanskyaAugust 22, 2025 | msn.comRocket Pharmaceuticals: Good News As Clinical Hold Lifted - But Challenges RemainAugust 22, 2025 | seekingalpha.comRocket Pharmaceuticals (RCKT) Receives a Sell from Goldman SachsAugust 22, 2025 | theglobeandmail.comRCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease StudyAugust 21, 2025 | zacks.comRocket Pharmaceuticals announces clinical hold lifted on RP-A501 trialAugust 20, 2025 | msn.comJohn Militello Sells 7,043 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockAugust 20, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells $33,706.22 in StockAugust 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCX, RCKT, FULC, and ABEO Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.89 +0.03 (+0.44%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.96 +0.07 (+1.07%) As of 09/5/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Fulcrum Therapeutics NASDAQ:FULC$7.66 +0.78 (+11.34%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.66 0.00 (0.00%) As of 09/5/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.OncoCyte NASDAQ:OCXOncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Rocket Pharmaceuticals NASDAQ:RCKT$3.28 +0.05 (+1.55%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.28 0.00 (0.00%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
